Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees

被引:0
作者
Babs E Verstrepen [1 ]
André Boonstra [2 ]
Gerrit Koopman [1 ]
机构
[1] Department of Virology,Biomedical Primate Research Centre,2280GH Rijswijk,The Netherlands
[2] Department of Gastroenterology and Hepatology,Erasmus University Medical Center Rotterdam,3015 CE Rotterdam,The Netherlands
关键词
Hepatitis C virus; Vaccines; Chimpanzees; Review; Prophylactic; Antibodies; T-cells;
D O I
暂无
中图分类号
R512.63 [];
学科分类号
100401 ;
摘要
Hepatitis C virus(HCV) infection is characterized by a high propensity for development of life-long viral persistence. An estimated 170 million people suffer from chronic hepatitis caused by HCV. Currently,there is no approved prophylactic HCV vaccine available.With the near disappearance of the most relevant animal model for HCV,the chimpanzee,we review the progression that has been made regarding prophylactic vaccine development against HCV. We describe the results of the individual vaccine evaluation experiments in chimpanzees,in relation to what has been observed in humans. The results of the different studies indicate that partial protection against infection can be achieved,but a clear correlate of protection has thus far not yet been defined.
引用
收藏
页码:53 / 69
页数:17
相关论文
共 50 条
[1]   Trace amounts of sporadically reappearing HCV RNA can cause infection [J].
Veerapu, Naga Suresh ;
Park, Su-Hyung ;
Tully, Damien C. ;
Allen, Todd M. ;
Rehermann, Barbara .
JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (08) :3469-3478
[2]   Confronting the Emerging Epidemic of HCV Infection Among Young Injection Drug Users [J].
Valdiserri, Ronald ;
Khalsa, Jag ;
Dan, Corinna ;
Holmberg, Scott ;
Zibbell, Jon ;
Holtzman, Deborah ;
Lubran, Robert ;
Compton, Wilson .
AMERICAN JOURNAL OF PUBLIC HEALTH, 2014, 104 (05) :816-821
[3]  
David Olagnier,John Hiscott.Type I and type III interferon‐induced immune response: It's a matter of kinetics and magnitude[J].Hepatology,2014(4)
[4]  
Mohamad S. Hakim,Michelle Spaan,Harry L. A. Janssen,Andre Boonstra.Inhibitory receptor molecules in chronic hepatitis B and C infections: novel targets for immunotherapy?[J].Rev. Med. Virol.,2014(2)
[5]  
Malcolm J. Macartney,Dianne Irish,Simon H. Bridge,Ana Garcia-Diaz,Clare L. Booth,Adele L. McCormick,Wendy Labbett,Colette Smith,Carmen Velazquez,Sudeep Tanwar,Paul Trembling,Michael Jacobs,Geoff Dusheiko,William Rosenberg,Tanzina Haque.Telaprevir or boceprevir based therapy for chronic hepatitis C infection: Development of resistance-associated variants in treatment failure[J].Antiviral Research,2014
[6]  
Donald B. Smith,Jens Bukh,Carla Kuiken,A. Scott Muerhoff,Charles M. Rice,Jack T. Stapleton,Peter Simmonds.Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource[J].Hepatology,2014(1)
[7]  
Abu S. Abdul-Quader,Jonathan Feelemyer,Shilpa Modi,Ellen S. Stein,Alya Briceno,Salaam Semaan,Tara Horvath,Gail E. Kennedy,Don C. Des Jarlais.Effectiveness of Structural-Level Needle/Syringe Programs to Reduce HCV and HIV Infection Among People Who Inject Drugs: A Systematic Review[J].AIDS and Behavior,2013(9)
[8]   A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C [J].
Sangro, Bruno ;
Gomez-Martin, Carlos ;
de la Mata, Manuel ;
Inarrairaegui, Mercedes ;
Garralda, Elena ;
Barrera, Pilar ;
Ignacio Riezu-Boj, Jose ;
Larrea, Esther ;
Alfaro, Carlos ;
Sarobe, Pablo ;
Jose Lasarte, Juan ;
Perez-Gracia, Jose L. ;
Melero, Ignacio ;
Prieto, Jesus .
JOURNAL OF HEPATOLOGY, 2013, 59 (01) :81-88
[9]  
Giuseppe Sautto,Alexander W. Tarr,Nicasio Mancini,Massimo Clementi,Roberto Burioni.Structural and Antigenic Definition of Hepatitis C Virus E2 Glycoprotein Epitopes Targeted by Monoclonal Antibodies[J].<journal-title>Clinical and Developmental Immunology,2013
[10]  
Mark AA Claassen,Harry LA Janssen,André Boonstra.Role of T cell immunity in hepatitis C virus infections[J].Current Opinion in Virology,2013